Compare Sanofi SA (SNY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Tango Therapeutics Inc. — how do they compare? Sanofi SA trades at $40.67 (market cap $94.58B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Sanofi SA is far larger — about 25.2× Tango Therapeutics Inc.'s market cap, and Sanofi SA pays a 6.18% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Tango Therapeutics Inc. for 0 Days on average.
| SNY | TNGX | |
|---|---|---|
Market Cap | $94.58B | $3.75B |
Volume | 3,988,460 | 9,619,106 |
Sector | Health | Health |
52-Week High | $52.34 | $32.90 |
52-Week Low | $39.12 | $7.50 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $113.80B | $2.77B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
